SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus ...

The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir should be made available for people seriously ill with COVID-19, despite limited data on its efficacy. The EMA’s human ...

When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Its monotherapy drug that is used to treat desmoid tumors has been approved in the United States. A transaction for Springworks would rank as one of the biggest pharma deals for Merck in recent ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.